Literature DB >> 15894657

Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.

Ji-Yeob Choi1, Kyoung-Mu Lee, Sue Kyung Park, Dong-Young Noh, Sei-Hyun Ahn, Hye-Won Chung, Wonshik Han, Jeong Soo Kim, Sang Goo Shin, In-Jin Jang, Keun-Young Yoo, Ari Hirvonen, Daehee Kang.   

Abstract

We examined whether common single nucleotide polymorphisms (SNP) in SULT1A1 (c.779G>A, *14A>G, and *85C>T) and SULT1E1 (IVS1-447C>A, IVS4-1653T>C, and *959G>A) genes influenced the risk and survival of breast cancer. Our study population consisted of 989 histologically confirmed sporadic breast cancer patients and 1,054 controls without history of cancer recruited from three teaching hospitals in Seoul. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated by logistic regression model. In the survival analysis for 529 breast cancer patients with completed treatments, the hazard ratios (HR) were calculated with Cox proportional hazard model. Women with the SULT1E1 *959 GA/AA genotype had a moderately decreased breast cancer risk compared with those with the GG genotypes (OR, 0.8; 95% CI, 0.70-1.00). When the haplotypes were considered, the homozygous *959 AA genotype together with the IVS4-1653 T>C base change (CTA-CCA haplotype) was associated with halved breast cancer risk (OR, 0.5; 95% CI, 0.24-0.88) compared with the wild type CTG-CTG haplotype. No other significant overall association was observed between the SULT1A1 and SULT1E1 SNPs nor haplotypes and breast cancer risk. When stratified by survival, patients with the SULT1E1 IVS4-1653 TC/CC genotypes showed a >3-fold risk of recurrence (HR, 3.2; 95% CI, 1.39-7.48) compared with those with the TT genotype. Moreover, when the haplotypes were considered, the SULT1E1 *959 G>A base change together with the IVS4-1653 T>C base change (CTG-CCA haplotype) was associated with a >4-fold risk of breast cancer (OR, 4.2; 95% CI, 1.15-15.15). These findings suggest that genetic polymorphisms of SULT1E1 are associated with increased risk and a disease free survival of breast cancer in Korean women.

Entities:  

Mesh:

Year:  2005        PMID: 15894657     DOI: 10.1158/1055-9965.EPI-04-0688

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  21 in total

1.  Effect of estrogen sulfation by SULT1E1 and PAPSS on the development of estrogen-dependent cancers.

Authors:  Yali Xu; Xiaoxia Liu; Fenghua Guo; Yanxia Ning; Xiuling Zhi; Xinhong Wang; Sifeng Chen; Lianhua Yin; Xiaobo Li
Journal:  Cancer Sci       Date:  2012-04-11       Impact factor: 6.716

2.  Pharmacogenetics of SULT1A1.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

3.  Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue.

Authors:  Yiwei Jiang; Liheng Zhou; Tingting Yan; Zhenzhou Shen; Zhimin Shao; Jinsong Lu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-21

4.  The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer.

Authors:  Chunhui Yi; Lina Mu; Irene A Rigault de la Longrais; Olga Sochirca; Riccardo Arisio; Herbert Yu; Aaron E Hoffman; Yong Zhu; Dionyssios Katsaro
Journal:  Breast Cancer Res Treat       Date:  2009-08-01       Impact factor: 4.872

5.  Impact of Human SULT1E1 Polymorphisms on the Sulfation of 17β-Estradiol, 4-Hydroxytamoxifen, and Diethylstilbestrol by SULT1E1 Allozymes.

Authors:  Amal A El Daibani; Fatemah A Alherz; Maryam S Abunnaja; Ahsan F Bairam; Mohammed I Rasool; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01       Impact factor: 2.441

6.  Risk factors and control strategies for the rapidly rising rate of breast cancer in Korea.

Authors:  Sue K Park; Yeonju Kim; Daehee Kang; En-Joo Jung; Keun-Young Yoo
Journal:  J Breast Cancer       Date:  2011-06-18       Impact factor: 3.588

7.  Garlic extract diallyl sulfide (DAS) activates nuclear receptor CAR to induce the Sult1e1 gene in mouse liver.

Authors:  Tatsuya Sueyoshi; William D Green; Kellie Vinal; Tyler S Woodrum; Rick Moore; Masahiko Negishi
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

8.  The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort.

Authors:  Eunjung Lee; Fredrick Schumacher; Juan Pablo Lewinger; Susan L Neuhausen; Hoda Anton-Culver; Pamela L Horn-Ross; Katherine D Henderson; Argyrios Ziogas; David Van Den Berg; Leslie Bernstein; Giske Ursin
Journal:  Breast Cancer Res       Date:  2011-04-01       Impact factor: 6.466

9.  SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

Authors:  Maria Tengström; Arto Mannermaa; Veli-Matti Kosma; Ari Hirvonen; Vesa Kataja
Journal:  BMC Cancer       Date:  2012-06-18       Impact factor: 4.430

Review 10.  SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Authors:  Katsuhisa Kurogi; Mohammed I Rasool; Fatemah A Alherz; Amal A El Daibani; Ahsan F Bairam; Maryam S Abunnaja; Shin Yasuda; Lauren J Wilson; Ying Hui; Ming-Cheh Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-06-30       Impact factor: 4.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.